Chronic myeloid leukaemia News and Research

RSS
Research reveals the mechanism that triggers breast cancer 'time bomb'

Research reveals the mechanism that triggers breast cancer 'time bomb'

World’s largest proteomics centre accelerates biomarker discoveries to improve people’s lives

World’s largest proteomics centre accelerates biomarker discoveries to improve people’s lives

Researchers apply CRISPR technology to eliminate fusion genes present in tumor cells

Researchers apply CRISPR technology to eliminate fusion genes present in tumor cells

Newly developed ChiTaRS database can collect cases of druggable fusion targets

Newly developed ChiTaRS database can collect cases of druggable fusion targets

CRISPR uncovers which gene fusions are critical for growth of cancer cells

CRISPR uncovers which gene fusions are critical for growth of cancer cells

Potential combination therapy against rare disease of the bone marrow could improve treatment

Potential combination therapy against rare disease of the bone marrow could improve treatment

OGT increases NGS cancer panel content to provide more flexibility for customization

OGT increases NGS cancer panel content to provide more flexibility for customization

Study provides new insight into development of immune cells

Study provides new insight into development of immune cells

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Scientists launch new virtual platform to aid global search for treatment of leukemia

Scientists launch new virtual platform to aid global search for treatment of leukemia

Delays in availability of new treatments and incomprehensible price rises disadvantage cancer patients

Delays in availability of new treatments and incomprehensible price rises disadvantage cancer patients

Leukaemia patients could safely reduce side effects of drug by cutting dose in half, study shows

Leukaemia patients could safely reduce side effects of drug by cutting dose in half, study shows

Salvage alloSCT remains option for progressing CML patients

Salvage alloSCT remains option for progressing CML patients

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Long-term dasatinib findings support first-line use in CML

Long-term dasatinib findings support first-line use in CML

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

CML treatment-free remission criteria outlined

CML treatment-free remission criteria outlined

BCR-ABL halving time indicates CML prognosis during front-line TKI

BCR-ABL halving time indicates CML prognosis during front-line TKI

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.